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ulation, particularly including children
with severe pulmonary hypertension.
Antonio F. Corno, MD, PD, FECTS, FRCS
Service de Chirurgie Cardio-vasculaire
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland
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Reply to the Editor:
We appreciate the kind comments of Dr
Corno in his letter regarding our article.1
We also appreciate his astute delineation of
the categories of congenital conditions in
which our technique could be applied clin-
ically. We wish to emphasize, however,
that ours is at this point an experimental
technique, confined to short-term applica-
tion in the experimental laboratory. We are
not advocating clinical application at this
time.
To address Dr Corno’s specific com-
ments, we need to distinguish between two
different experimental procedures devel-
oped in our laboratory, which are easily
confused because both rely on surgical sep-
aration of the right and left ventricles into
independent units. In the experiments to
which the letter is addressed, we trans-
planted an accessory donor right heart onto
a complete recipient heart, the accessory
right heart transplantation procedure. This
is being investigated as an alternative treat-
ment for congenital hypoplastic lesions of
the right side of the heart in children. In an
earlier series of experiments,2 we reported
an experimental right heart–sparing proce-
dure in which the right ventricle of a recip-
ient is preserved and a complete donor
heart is implanted. This latter procedure is
intended, in principle, for human recipients
with severe ambient pulmonary hyperten-
sion, a setting in which right heart failure,
possibly lethal, is frequently encountered.
Both these experimental operations rely on
the physical separation of right and left
sides of the heart, but they represent essen-
tially converse procedures for completely
disparate indications.
Dr Corno enumerates other operations
that may have application to patient groups
with right ventricular hypoplasia or clinical
decompensation after conventional pallia-
tive surgery. We agree that the one-and-a-
half ventricular repair about which he and
others have published has merit. This ap-
proach allows a bidirectional Glenn shunt
to perfuse the lungs with the superior vena
caval flow, while the diminutive right ven-
tricle continues to pump the inferior vena
caval flow to the pulmonary artery. We
hasten to point out that this repair uses the
native one-and-a-half ventricles and should
not be confused with our right ventricle–
sparing transplant operation,2 which has at
times been called the “heart-and-a-half”
operation.
We agree fully that the acute experi-
ments presented in our article did not sub-
ject the accessory right heart to ambient
pulmonary hypertension. In related exper-
iments currently in press,3 our converse
procedure of right ventricle–sparing trans-
plantation did successfully cope with se-
vere induced iatrogenic pulmonary hyper-
tension.
We agree that heterotopic transplanta-
tion represents a viable solution in many
situations in which pulmonary hyperten-
sion precludes traditional orthotopic car-
diac transplantation. In short-term experi-
ments, Corno and colleagues used the left
ventricle of a full heterotopic transplant to
perfuse the right-sided circulation. There
are several advantages to transplanting an
isolated right heart. The operation can be
done without cardiopulmonary bypass.
Space issues are minimized, because there
is no left ventricle. Finally, the potential
donor pool is quite large and different from
the standard donor pool, because hearts
with left ventricular dysfunction may be
acceptable. In fact, such hearts might even
be preferable, because they have “precon-
ditioned” the right ventricle against left
ventricular failure.
Standard heterotopic transplantation,
described in the early era of clinical cardiac
transplantation, continues to be quite lim-
ited in application, largely because of prob-
lems of embolization and arrhythmias orig-
inating in the preserved native left ventricle
and because of mass effects of the hetero-
topic heart in the pulmonary space. Our
right heart–sparing transplant procedure
was designed to avoid these problems.
We congratulate Dr Corno on the im-
portant work he has highlighted and thank
him for his insightful commentary on our
recent article.
John A. Elefteriades, MD
Gary S. Kopf, MD
Section of Cardiothoracic Surgery
Yale University School of Medicine
New Haven, CT 06510
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The radial artery: Neither gold, nor
silver, but bronze?
To the Editor:
I greatly appreciated reading Dr Lytle’s
insightful comments in his editorial on
the radial artery (RA) versus the right
internal thoracic artery (RITA) as a sec-
ond arterial conduit for coronary sur-
gery.1 All that he says is true: the RITA
graft, when considering its historical
older brother the left internal thoracic
artery (LITA) graft, should have the same
long-term potential but technically poses
a bigger challenge. Hence surgeons opt
for a more user-friendly arterial conduit,
the RA. I would like to suggest a differ-
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ent comparison/substitute: the RA for the
vein graft. Dr Lytle’s comment in his
editorial, “in my judgment, the RA graft
is less predictable than the RITA graft in
regard to patency,” intrigued me. Over
the past 15 years as a practicing cardio-
thoracic surgeon, I have become pro-
foundly aware of the inadequacy of
veins, and since my recent attendance at
the enlightening and energy-invoking
symposium “Arterial Conduits for Myo-
cardial Revascularization” in Rome by
Dr G. F. Possatti and Dr A. M. Calafiore,
I believe the thrust should be to continue
to use double ITA grafts whenever pos-
sible (especially in the young) but to sub-
stitute the RA for the vein graft. Since
my return from this symposium, I have
tried to do this; perhaps I did not see (or
did not want to see) before, but many
patients have serious venous disease of
their legs precluding use of the saphe-
nous vein. I think one of the turning
points for me was when I recently (July
24, 2003) had to reoperate on an 83-year-
old woman, on whom I had placed 2
grafts at age 81. Her LITA had gone
down, I believe because I placed the graft
inadvertently above a stenosis and her
vein graft to a marginal artery occluded.
If her vein graft had stayed open, she
probably would not have needed reopera-
tion at age 83. I used a sequential RA
graft to the left anterior descending cor-
onary artery and the marginal branch on-
pump, and postoperatively she woke up
stating that this was easier than her first
operation. (Obviously this time both
grafts were working!)
A second reason to substitute the vein
for the RA graft could be the anticipated
longer-lasting results of the drug-eluting
stents used by interventional cardiolo-
gists. I know we are all interested in the
same end—stamping out coronary artery
disease effects— but it can be a little dis-
concerting for many surgeons currently
in practice to see their favored coronary
artery bypass grafts (LITA plus 2 veins)
going the way of the dodo bird. I want to
be so bold as to predict that the drug-
eluting stents will rival our saphenous
vein grafts (that is, by the time they fig-
ure out which drug, from which drug
family, how much eluting, over what pe-
riod of time, and so on, works; it might
take 20 years). Although we should never
be competitive with our interventional
colleagues because we have the same end
point in common, we must as surgeons
find something ancillary to their work. I
believe total arterial grafting (be it bilat-
eral ITA, LITA/RA, RITA, bilateral ITA/
gastroepiploic artery) may well be the
answer. As Dr Lytle most wisely stated at
the 2003 meeting of The American As-
sociation for Thoracic Surgery in Boston
(and I quote him often in this): “Did you
think you were going to be doing the
same operation for 100 years!?” Dr Lytle
continues to be a driving force leading all
our quests for the best coronary artery
bypass conduit.
Teresa Kieser, MD, FRCSC, FACS
Department of Cardiac Sciences
Calgary Health Region Foothills Medical
Centre
Calgary, Alberta, Canada
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Angiotensin-converting enzyme
inhibitors predispose to hypotension
refractory to norepinephrine but
responsive to methylene blue
To the Editor:
We read with interest the brief communi-
cation of Grayling and Deakin1 describing
the methylene blue administration in a pa-
tient with refractory hypotension during
cardiac surgery. We’re currently using this
drug for patients with high cardiac output
and hypotension unresponsive to norepi-
nephrine at doses similar to those sug-
gested by Grayling and Deakin (up to 3
mg/kg in 2 different administration instead
of 2 mg/kg in a single dose). We would like
to suggest a possible predisposing factor of
vasoplegia that responds to methylene
blue: in our experience2 and in the litera-
ture3-5 it is evident that most episodes of
refractory hypotension are related to pre-
operative intake of angiotensin-converting
enzyme inhibitors (ACEI); even the patient
described in this report was assuming
ACEI (ramipril). After experiencing a dra-
matic refractory hypotension in a patient on
a program of ACEI,2 we started using
methylene blue in case of refractory hypo-
tension and withdrawing ACEI the day be-
fore surgery. We observed an immediate
and sustained response even at doses less
than 1 mg/kg.
We would like to reinforce this kind of
therapeutic approach and suggest a com-
mon predisposing factor that has been so
far underestimated: preoperative intake of
ACEI.
Donatella Sparicio, MD
Giovanni Landoni, MD
Alberto Zangrillo, MD
Vita-Salute University of Milano, IRCCS San
Raffaele Hospital
Milano, Italy
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Modified Fontan procedure in adults
To the Editor:
At the outset I must congratulate and thank
the authors of this article for this landmark
work on the Fontan procedure in an adult
population.1 This is going to be a bench-
mark for adult Fontan procedure in years to
come.
In the Western hemisphere the Fontan
surgery is done in children; adult patients
undergoing this procedure are exceptions,
not the rule. But in developing countries
adult patients for univentricular palliation,
with or without prior surgical palliation,
are quite common.2 As the authors have
addressed, the primary issue for these pa-
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